Lifeboat Foundation

In “2030: Beyond the Film” Director Johnny Boston discusses the futurist FM-2030, the Coronavirus Pandemic, and a range of urgent issues in the medical, philosophical, longevity & futurist space with leading voices.

In this episode, Boston talks with David A. Kekich on why Kekich believes working towards Biological Superlongevity should be the first goal of Transhumanists and futurists.

Continue reading “Beyond 2030: David A. Kekich on Working Towards Biological Superlongevity” »

One of the world’s greatest anti-aging scientists continues his groundbreaking efforts. In the photo next to Dr David Sinclair, there is a fella who kind of looks like my friend, Dr Yuancheng Ryan Lu. Is that you? (Dr Lu has confirmed that he is indeed the scientist on the right. Dr Sinclair is on the left.)

I can’t wait to see what they develop next!

Harvard scientist David Sinclair is one of Longevity’s big hitters. Just a year after raising $50M in Series B financing, his company Life Biosciences LLC is looking for $100M to progress its anti-aging research [1].

Continue reading “David Sinclair seeks £100m for anti-aging fight” »

With comments from Aubrey de Grey.

Bret Weinstein was interviewed on the Joe Rogan show and Bret claimed that the breeding protocols and telomeres of lab mice are broken. Bret claims that this problem is so severe that it calls into question the safety and correctness of decades of pharmaceutical studies.

Continue reading “Lab Mice Telomeres Do Not Break Them as Disease Models” »

#nugencis #nugenicsresearch #humanlongevity #agereversal #blissatomic
Dr. Harold has been a pioneer in the field of cancer research, in the development of modern aspects of gene hunting and sequencing. He carries expertise in bioinformatics, chronobiology, and biotechnology and is currently working in the capacity of Chief Technical Officer at Nugenics Research Pvt Ltd. exploring in anti-aging modalities.
They recently released a paper online on #biorxiv regarding their breakthrough research on Human Age Reversal using Young Blood #plasma, the paper’s authors include recognized Longevity academician Steve Horvath.

The paper also caught the attention of #davidsinclair the leading researcher/voice in the field of Human Longevity.
Dr Katcher spoke about how & why he moved from cancer research to Human Longevity, his research & results of 54% age reversal in Rats, his partner #akshaysanghavi, the future road map/timelines on how & when this might be commercially available.

Continue reading “Breakthrough in Age Reversal With Youngblood Plasma — Dr Harold Katcher — CTO Nugenics Research” »

Differences in the rate that genetic mutations accumulate in healthy young adults could help predict remaining lifespan in both sexes and the remaining years of fertility in women, according to University of Utah Health scientists. Their study, believed to be the first of its kind, found that young adults who acquired fewer mutations over time lived about five years longer than those who acquired them more rapidly.

The researchers say the discovery could eventually lead to the development of interventions to slow the aging process.

“If the results from this small study are validated by other independent research, it would have tremendous implications,” says Lynn B. Jorde, Ph.D., chair of the Department of Human Genetics at U of U Health and a co-author of the study. “It would mean that we could possibly find ways to fix ourselves and live longer and better lives.”

Liz Parrish has more or less had a real-life ‘Death Becomes Her’ moment. But instead of drinking a magic potion that promises eternal youth, she claims to have become the first person in the world to take dual gene therapies to reverse ageing.

A rejuvenation roadmap, and some info on Rejuvenate Bio.

Ray Kurzweil predicted the Technological Singularity will be reached in 2045. This actually means there will be strong AI, something like AGI that is 1 billion times more capable than the human brain in many aspects.

New chain lube claims to save seven watts and last 1800km per application.

Chimeric antigen receptor (CAR) T cells have transformed the treatment of refractory blood cancers. These genetically engineered immune cells seek out and destroy cancer cells with precision. Now, scientists at Memorial Sloan Kettering are deploying them against other diseases, including those caused by senescence, a chronic “alarm state” in tissues. The scope of such ailments is vast and includes debilitating conditions, such as fibrotic liver disease, atherosclerosis, and diabetes.

Key to the success of CAR T cell therapy has been finding a good target. The first US Food and Drug Administration-approved CAR T cells target a molecule on the surface of blood cancers called CD19. It is present on cancer cells but few other normal cells, so side effects are limited.

Taking their cue from this prior work, a team of investigators including Scott Lowe, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, and Michel Sadelain, Director of the Center for Cell Engineering at MSK, along with their trainees Corina Amor, Judith Feucht, and Josef Leibold, sought to identify a target on senescent cells. These cells no longer divide, but they actively send “help me” signals to the immune system.